GSK's new triple lung drug beats other modern inhalers in study
September 20, 2017 at 03:17 AM EDT
LONDON, Sept 20 (Reuters) - GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.